Skip to main content

Table 4 Effect of TMS1/ASC gene methylation on clinical stage (II or III), and Gleason score (6 or 7).

From: Methylation mediated silencing of TMS1/ASC gene in prostate cancer

 

Number and (%) of tissues with TMS1/ASC methylation

Age-adjusted odds-ratio* (95% CI)

P-value

Clinical stage

   

   II (reference)

28/42 (66.7)

  

   III

11/19 (57.9)

0.7 (0.2 – 2.1)

0.53

Gleason score

   

   6 (reference)

14/26 (53.9)

  

   7

23/32 (71.9)

2.3 (0.7 – 7.2)

0.15

  1. * Age-adjusted relative risk estimates of stage III vs. II, or Gleason score 7 vs. 6, derived from logistic model ln (p/q) = b0 + b1 × TMS1/ASC + b2 × Age, where p is either the probability of having stage III disease or of having Gleason score 7, and q = (1-p) is the probability of the other category.
Back to article page

Molecular Cancer

ISSN: 1476-4598